Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy-Reference-Cited by-同舟云学术

Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

Published:2008-03-18 Issue:5 Volume:5 Page:268-278
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Loriot Yohann,Perlemuter Gabriel,Malka David,Penault-Lorca Frédérique,Boige Valérie,Deutsch Eric,Massard Christophe,Armand Jean Pierre,Soria Jean-Charles

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc1087.pdf

Reference67 articles.

1. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70

2. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

3. Fukuoka M et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21: 2237–2246

4. Wacker B et al. (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13: 3913–3921

5. Perez-Soler R et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238–3247

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs;PLOS ONE;2024-01-24

2. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer;Cancer Control;2024-01

3. Modeling Tumor Cell Dormancy in an Ex Vivo Liver Metastatic Niche;Methods in Molecular Biology;2024

4. Breast Cancer;Side Effects of Cancer Therapy;2023-11-23

5. Primary tumor location is a risk factor for postoperative development of sarcopenia related to poor outcomes in patients with colorectal cancer;2023-06-01